bioAffinity's CyPath Lung Test Volume Surges 216% Year-Over-Year
Event summary
- CyPath Lung test volume increased 216% year-over-year in Q2 2026, with revenue up 159% to $835,000 for the first half of 2026.
- The number of physician offices and clinics ordering CyPath Lung rose 122% during Q2 2026 compared to the same period in 2025.
- A longitudinal clinical trial evaluating CyPath Lung's performance began patient enrollment at 11 sites, including VA and military medical centers.
- bioAffinity completed a $3.2 million public offering in June 2026 to support commercialization and development activities.
The big picture
bioAffinity's strong commercial momentum reflects growing physician confidence in CyPath Lung as a noninvasive tool for early lung cancer detection. The company's strategic focus on expanding clinical validation and broadening its diagnostic and therapeutic pipeline positions it to capture a larger share of the lung disease and skin cancer markets. With increasing adoption among VA and military medical centers, bioAffinity is well-positioned to leverage its technology in high-need patient populations.
What we're watching
- Commercial Expansion
- How bioAffinity will sustain the rapid adoption of CyPath Lung among new healthcare systems and specialty practices.
- Clinical Validation
- Whether the ongoing longitudinal clinical trial will further solidify CyPath Lung's clinical performance metrics.
- Therapeutic Pipeline
- The pace at which bioAffinity advances its topical treatments for skin cancers and diagnostic platform for asthma and COPD.
Related topics